Neck circumference in relation to glycemic parameters: a systematic review and meta-analysis of observational studies.
Fasting plasma glucose
Glycated hemoglobin
Insulin levels
Insulin resistance
Neck circumference
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
04
2019
accepted:
18
06
2019
entrez:
11
7
2019
pubmed:
11
7
2019
medline:
11
7
2019
Statut:
epublish
Résumé
Recent studies have suggested that neck circumference (NC) is a supplemental screening measure for diagnosing metabolic complications and might be associated with glycemic parameters. The aim of the present study was to to evaluate the association between NC and glycemic parameters. We systematically searched the electronic databases (including MEDLINE, Scopus, EMBASE, and Google scholar) up to April 2018. Observational studies that reported correlation coefficient between NC and glycemic parameters were included in the analysis. A random effects model was used to estimate overall Fisher's Z and 95% confidence interval of glycemic parameters including fasting plasma glucose (FBG), serum fasting insulin level, homeostasis model assessment-estimated insulin resistance (HOMA-IR) and glycated hemoglobin (HbA1c). A total of 21 studies (44,031 participants) were eligible for including in the systematic review and meta-analysis. Significant correlations were found between NC and FBG (Fisher's Z = 0.18; 95% CI 0.16, 0.21), serum fasting insulin level (Fisher's Z = 0.34; 95% CI 0.26, 0.41), HOMA-IR (Fisher's Z = 0.36; 95% CI 0.29, 0.43) and HbA1c (Fisher's Z = 0.14; 95% CI 0.09, 0.20). Meta-regression analysis showed that NC were marginally associated with FBG in a linear manner (β = 0.008, P = 0.09); but not related to serum fasting insulin level, HOMA-IR, and HbA1c. This meta-analysis of cross-sectional studies showed that NC was positively correlated with glycemic parameters including FBG, serum fasting insulin level, HOMA-IR, and HbA1c. Further investigations with prospective design are required to confirm these findings.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have suggested that neck circumference (NC) is a supplemental screening measure for diagnosing metabolic complications and might be associated with glycemic parameters. The aim of the present study was to to evaluate the association between NC and glycemic parameters.
METHODS
METHODS
We systematically searched the electronic databases (including MEDLINE, Scopus, EMBASE, and Google scholar) up to April 2018. Observational studies that reported correlation coefficient between NC and glycemic parameters were included in the analysis. A random effects model was used to estimate overall Fisher's Z and 95% confidence interval of glycemic parameters including fasting plasma glucose (FBG), serum fasting insulin level, homeostasis model assessment-estimated insulin resistance (HOMA-IR) and glycated hemoglobin (HbA1c).
RESULTS
RESULTS
A total of 21 studies (44,031 participants) were eligible for including in the systematic review and meta-analysis. Significant correlations were found between NC and FBG (Fisher's Z = 0.18; 95% CI 0.16, 0.21), serum fasting insulin level (Fisher's Z = 0.34; 95% CI 0.26, 0.41), HOMA-IR (Fisher's Z = 0.36; 95% CI 0.29, 0.43) and HbA1c (Fisher's Z = 0.14; 95% CI 0.09, 0.20). Meta-regression analysis showed that NC were marginally associated with FBG in a linear manner (β = 0.008, P = 0.09); but not related to serum fasting insulin level, HOMA-IR, and HbA1c.
CONCLUSIONS
CONCLUSIONS
This meta-analysis of cross-sectional studies showed that NC was positively correlated with glycemic parameters including FBG, serum fasting insulin level, HOMA-IR, and HbA1c. Further investigations with prospective design are required to confirm these findings.
Identifiants
pubmed: 31289463
doi: 10.1186/s13098-019-0445-7
pii: 445
pmc: PMC6593610
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
50Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Clin Invest. 2000 Aug;106(4):473-81
pubmed: 10953022
Obes Res. 2001 Aug;9(8):470-7
pubmed: 11500527
Int J Obes Relat Metab Disord. 2002 Jun;26(6):873-5
pubmed: 12037660
Obes Rev. 2002 Aug;3(3):217-24
pubmed: 12164475
Clin Endocrinol (Oxf). 2002 Dec;57(6):769-78
pubmed: 12460327
Obes Res. 2003 Feb;11(2):226-31
pubmed: 12582218
J Clin Invest. 2004 Jun;113(11):1582-8
pubmed: 15173884
Clin Sci (Lond). 2005 Aug;109(2):143-59
pubmed: 16033329
Nature. 2006 Dec 14;444(7121):840-6
pubmed: 17167471
J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):283-90
pubmed: 18167644
Trends Endocrinol Metab. 1996 Nov;7(9):311-9
pubmed: 18406764
Exp Clin Cardiol. 2006 Spring;11(1):14-20
pubmed: 18651013
Diabetologia. 1976 Dec;12(6):563-71
pubmed: 187517
Clin Nutr. 2009 Feb;28(1):46-51
pubmed: 19010573
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Clin Endocrinol (Oxf). 2010 Aug;73(2):197-200
pubmed: 20050862
J Clin Endocrinol Metab. 2010 Aug;95(8):3701-10
pubmed: 20484490
Diabetes Care. 2010 Nov;33(11):2465-7
pubmed: 20724650
Diabetes Care. 2011 Apr;34(4):1026-31
pubmed: 21378212
Rev Assoc Med Bras (1992). 2011 Sep-Oct;57(5):559-64
pubmed: 22012291
J Pak Med Assoc. 2012 Jan;62(1):36-40
pubmed: 22352099
Hiroshima J Med Sci. 2011 Dec;60(4):71-8
pubmed: 22389950
Clin Endocrinol (Oxf). 2013 Jun;78(6):874-81
pubmed: 22804918
Diabetes Metab Res Rev. 2013 Jan;29(1):90-7
pubmed: 23135790
N Am J Med Sci. 2013 Jan;5(1):28-31
pubmed: 23378952
Int J Clin Pract. 2013 Mar;67(3):217-24
pubmed: 23409690
Cardiovasc Diabetol. 2013 May 16;12:76
pubmed: 23680280
Diabetes Metab Res Rev. 2014 Jan;30(1):69-76
pubmed: 23996612
Clin Cardiol. 2014 Jul;37(7):402-7
pubmed: 24648005
J Clin Diagn Res. 2014 Jul;8(7):MC23-5
pubmed: 25177592
Am J Clin Nutr. 2014 Nov;100(5):1244-51
pubmed: 25332322
Diabetol Metab Syndr. 2014 Nov 01;6(1):116
pubmed: 25400699
J Hypertens. 2015 Feb;33(2):275-8
pubmed: 25545838
Hiroshima J Med Sci. 2014 Dec;63(4):27-32
pubmed: 25707090
Nutr Metab (Lond). 2015 Dec 30;12:63
pubmed: 26719755
Int J Clin Exp Med. 2015 Oct 15;8(10):19107-13
pubmed: 26770540
J Atheroscler Thromb. 2016 Jun 1;23(6):728-36
pubmed: 26797264
Metab Syndr Relat Disord. 2016 Apr;14(3):145-53
pubmed: 26824404
J Diabetes Res. 2016;2016:6058916
pubmed: 26981543
Endocr Res. 2017 Feb;42(1):6-14
pubmed: 27050332
Indian J Endocrinol Metab. 2016 Nov-Dec;20(6):831-837
pubmed: 27867888
Am J Med. 2017 Aug;130(8):958-966.e1
pubmed: 28238696
Curr Diabetes Rev. 2018;14(5):464-471
pubmed: 28969558
Front Physiol. 2017 Nov 29;8:965
pubmed: 29238304
Nutr Diabetes. 2018 Mar 13;8(1):14
pubmed: 29549249
Nutr Metab Cardiovasc Dis. 2018 Jul;28(7):657-674
pubmed: 29779782
Diabetol Metab Syndr. 2018 Sep 29;10:72
pubmed: 30288175
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Clin Invest. 1995 Nov;96(5):2297-303
pubmed: 7593616
J Clin Invest. 1993 Jul;92(1):91-8
pubmed: 8326021